Updated Jul 16, 2026
BVF PARTNERS L P/IL has filed 5 SEC Form 4 filings across 4 companies in the last 90 days — active on both sides. Lifetime open-market purchases: $31.30M. Lifetime open-market sales: $361.57M. Historical track record: 5/5 stars across 6 tracked purchases.
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★★★★★ (5/5) |
|---|---|
| Total purchases tracked | 6 |
| Purchases with forward-return data | 6 |
| 30-day win rate | 10000% |
| 90-day win rate | 10000% |
| Avg 5-day return | +1746.50% |
| Avg 30-day return | +1539.52% |
| Avg 90-day return | +3192.82% |
| Best 30-day return | +2980.50% |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-26 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 51.9K | $106.50 | $5.52M |
| 2026-06-26 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 113.3K | $106.50 | $12.07M |
| 2026-06-26 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 627.6K | $106.50 | $66.84M |
| 2026-06-26 | KYMR | Kymera Therapeutics, Inc. | S — Open-market sale | 837.9K | $106.50 | $89.24M |
| 2026-05-18 | XOMA | XOMA Royalty Corp | J — Other acquisition / disposition | 772.0K | $4.03 | $3.11M |
| 2026-05-18 | XOMA | XOMA Royalty Corp | J — Other acquisition / disposition | 412.0K | $4.03 | $1.66M |
| 2026-05-18 | XOMA | XOMA Royalty Corp | J — Other acquisition / disposition | 1.51M | $4.03 | $6.07M |
| 2026-05-18 | XOMA | XOMA Royalty Corp | J — Other acquisition / disposition | 2.31M | $4.03 | $9.32M |
| 2026-04-02 | MLTX | MoonLake Immunotherapeutics | S — Open-market sale | 248.5K | $16.79 | $4.17M |
| 2026-04-02 | MLTX | MoonLake Immunotherapeutics | S — Open-market sale | 1.57M | $16.79 | $26.35M |
| 2026-04-02 | MLTX | MoonLake Immunotherapeutics | S — Open-market sale | 1.93M | $16.79 | $32.44M |
| 2026-01-30 | RPTX | Repare Therapeutics Inc. | J — Other acquisition / disposition | 548.9K | — | |
| 2026-01-30 | RPTX | Repare Therapeutics Inc. | J — Other acquisition / disposition | 4.31M | — | |
| 2026-01-30 | RPTX | Repare Therapeutics Inc. | J — Other acquisition / disposition | 5.31M | — | |
| 2025-10-09 | EPIX | ESSA Pharma Inc. | J — Other acquisition / disposition | 560.8K | — | |
| 2025-10-09 | EPIX | ESSA Pharma Inc. | J — Other acquisition / disposition | 4.73M | — | |
| 2025-10-09 | EPIX | ESSA Pharma Inc. | J — Other acquisition / disposition | 6.19M | — | |
| 2025-08-05 | EPIX | ESSA Pharma Inc. | S — Open-market sale | 11 | $1.88 | $21 |
| 2025-08-05 | EPIX | ESSA Pharma Inc. | S — Open-market sale | 66 | $1.88 | $124 |
| 2025-08-05 | EPIX | ESSA Pharma Inc. | S — Open-market sale | 79 | $1.88 | $148 |
BVF PARTNERS L P/IL is a corporate insider — currently tracked as Director of Kymera Therapeutics, Inc. (KYMR). InsiderAlpha tracks every SEC Form 4 filing in real time.
5 primary Form 4 filings in the last 90 days, covering 4 companies.
Recorded transactions: 6 open-market purchases ($31.30M) and 18 open-market sales ($361.57M) across all tracked filings.
Across 6 tracked purchases, BVF PARTNERS L P/IL averaged +1539.5% avg 30-day return with a 10000% 30-day win rate. InsiderAlpha rates the track record at 5/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live BVF PARTNERS L P/IL profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.